Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: A hellenic cooperative oncology group study

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 2, 2008, Pages 277-284

  Briasoulis, E ^a   Fountzilas, G ^b   Bamias, A ^c   Dimopoulos, M A ^c   Xiros, N ^d   Aravantinos, G ^e   Samantas, E ^e   Kalofonos, H ^f   Makatsoris, T ^f   Mylonakis, N ^g   Papakostas, P ^h   Skarlos, D ⁱ   Varthalitis, I ^j   Pavlidis, N ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^e General Oncology Hospital Agioi Anargyroi   (Greece)

^f UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^g METAXA CANCER HOSPITAL   (Greece)

^h HIPPOKRATION HOSPITAL   (Greece)

ⁱ IASO GENERAL HOSPITAL   (Greece)

^j Hania General Hospital   (Greece)

more..

Author keywords

Chemotherapy; Irinotecan; Oxaliplatin; Phase II; Trial; Unknown primary carcinoma

Indexed keywords

ANTIEMETIC AGENT; ATROPINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CELL COUNT; BONE METASTASIS; CANCER GROWTH; CANCER OF UNKNOWN PRIMARY SITE; CANCER SURVIVAL; CHOLINERGIC SYNDROME; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; LEUKOPENIA; LIVER DISEASE; LIVER METASTASIS; MALE; MEDICAL DECISION MAKING; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LOCALIZATION; VISCERAL METASTASIS; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; ORGANOPLATINUM COMPOUNDS;

EID: 43749089186     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0604-7     Document Type: Article

References (39)

1. Briasoulis E, Pavlidis N (1997) Cancer of unknown primary origin. Oncologist 2:142-152
2. Muir C (1995) Cancer of unknown primary site. Cancer 75:353-356
3. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39:1990-2005
4. Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL (1998) Unknown primary tumors metastatic to liver. J Clin Oncol 16:2105-2112
5. Briasoulis E, Kalofonos H, Bafaloukos D, et al (2000) Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic cooperative oncology group study. J Clin Oncol 18:3101-3107
6. Pentheroudakis G, Briasoulis E, Karavassilis V, et al (2005) Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective? Acta Oncol 44:155-160
7. Armstrong AC, Blackhall FH (2007) Management of cancer from an unknown primary. Expert Opin Pharmacother 8:445-455
8. Briasoulis E, Tsavaris N, Fountzilas G, et al (1998) Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: a Hellenic co-operative oncology group phase II study. Oncology 55:426-430
9. Strnad CM, Grosh WW, Baxter J, et al (1989) Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. Ann Intern Med 111:213-217
10. Hainsworth JD, Greco FA (1993) Treatment of patients with cancer of an unknown primary site. N Engl J Med 329:257-263
11. Yakushiji S, Ando M, Yonemori K, et al (2006) Cancer of unknown primary site: review of consecutive cases at the national cancer center hospital of Japan. Int J Clin Oncol 11:421-425
12. Kawato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T, Matsumoto K (1991) Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 28:192-198
13. Vaisman A, Varchenko M, Umar A, et al (1998) The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58:3579-3585
14. Judson I, Kelland LR (2000) New developments and approaches in the platinum arena. Drugs 59(Suppl 4):29-36
15. Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F (1999) Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 5:1189-1196
16. Tanaka R, Ariyama H, Qin B, et al (2005) Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro. Oncol Rep 14:683-688
17. Monnet I, Brienza S, Hugret F, et al (1998) Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le traitement des tumeurs intra thoraciques. Eur J Cancer 34:1124-1127
18. Conroy T, Paillot B, Francois E, et al (2005) Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer-a groupe tumeurs digestives of the Federation nationale des centres de lutte contre le cancer study. J Clin Oncol 23:1228-1236
19. Hoff PM, Wolff RA, Xiong H, et al (2006) Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer. Cancer 106:2241-2246
20. Bidoli P, Zilembo N, Cortinovis D, et al (2007) Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian trials in medical oncology study. Ann Oncol 18:461-467
21. Wasserman E, Cuvier C, Lokiec F, et al (1999) Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol 17:1751-1759
22. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92:205-216
23. Briasoulis E, Pavlidis N (2007) Cancers of unknown primary site: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 18(Suppl 2):ii81-ii82
24. van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF (2002) Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer 38:409-413
25. Levi F, Te VC, Erler G, Randimbison L, La Vecchia C (2002) Epidemiology of unknown primary tumours. Eur J Cancer 38:1810-1812
26. Pavlidis N (2007) Forty years experience of treating cancer of unknown primary. Acta Oncol 46:592-601
27. Parnis FX, Olver IN, Kotasek D, et al (2000) Phase II study of epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) for carcinoma of unknown primary site. Ann Oncol 11:883-884
28. Dowell JE, Garrett AM, Shyr Y, Johnson DH, Hande KR (2001) A randomized phase II trial in patients with carcinoma of an unknown primary site. Cancer 91:592-597
29. Greco FA, Burris HA III, Litchy S, et al (2002) Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie pearl cancer research Network study. J Clin Oncol 20:1651-1656
30. Culine S, Fabbro M, Ychou M, Romieu G, Cupissol D, Pinguet F (2002) Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site. Cancer 94:840-846
31. Pittman KB, Olver IN, Koczwara B, et al (2006) Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide cancer trials and education collaborative study. Br J Cancer 95:1309-1313
32. Berry W, Elkordy M, O'rourke M, Khan M, Asmar L (2007) Results of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: a reasonable regimen for the community-based clinic? Cancer Invest 25:27-31
33. Pentheroudakis G, Briasoulis E, Pavlidis N (2007) Cancer of unknown primary site: missing primary or missing biology? Oncologist 12:418-425
34. Hainsworth JD, Erland JB, Kalman LA, Schreeder MT, Greco FA (1997) Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 15:2385-2393
35. Karavasilis V, Malamou-Mitsi V, Briasoulis E, et al (2005) Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer 5:25
36. Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA (2007) Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie pearl cancer research Network. J Clin Oncol 25:1747-1752
37. Pentheroudakis G, Pavlidis N (2006) Perspectives for targeted therapies in cancer of unknown primary site. Cancer Treat Rev 32:637-644
38. Hurwitz H, Fehrenbacher L, Novotny W, et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
39. Sandler A, Gray R, Perry MC, et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550